
Medical Devices · NYSE: RMD
ResMed earnings: results, call transcripts & KPI history
2 quarters · fiscal year ends June · next results expected around 28 Jan 2027
Latest: Q1 FY2027
ResMed closed the MatrixCare divestiture and launched the AirTouch F40 fabric mask, refocusing on core sleep and breathing health and its connected digital ecosystem.
ResMed's quarter was driven by demand for sleep devices and masks in both the Americas and the rest of the world. It launched the AirTouch F40, its third fabric mask, plus the AirCurve 11 ST/ST-A bilevel device in the U.S. It also closed the MatrixCare sale and added partnerships with Eight Sleep and ŌURA to bring more people into sleep care.
Read the Q1 FY2027 summary →Q1 FY2027 slides (PDF) ↗Official transcript (PDF) ↗
Quarters
KPI history
Fourth quarter worked out from the annual figure.
Data
| Q2 FY25 | $1.3B |
| Q3 FY25 | $1.3B |
| Q4 FY25 | $1.3B * |
| Q1 FY26 | $1.3B |
| Q2 FY26 | $1.4B |
| Q3 FY26 | $1.4B |
| Q4 FY26 | $1.5B * |
| Q1 FY27 | $1.4B |
Data
| Q2 FY25 | $2.34 |
| Q3 FY25 | $2.48 |
| Q1 FY26 | $2.37 |
| Q2 FY26 | $2.68 |
| Q3 FY26 | $2.74 |
| Q1 FY27 | $2.92 |
Fourth-quarter EPS appears once the press release is read; filings report it only for the full year.
Data
| Q2 FY25 | 32.5% |
| Q3 FY25 | 33.0% |
| Q4 FY25 | 33.7% |
| Q1 FY26 | 33.4% |
| Q2 FY26 | 34.6% |
| Q3 FY26 | 34.9% |
| Q4 FY26 | 30.7% |
| Q1 FY27 | 32.0% |
Data
| Q2 FY25 | $288.0M |
| Q3 FY25 | $557.9M |
| Q4 FY25 | $508.2M |
| Q1 FY26 | $414.4M |
| Q2 FY26 | $311.2M |
| Q3 FY26 | $520.5M |
| Q4 FY26 | $403.5M |
| Q1 FY27 | $373.7M |
Operating cash flow minus capital expenditure, from cash flow statements.
| Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.3B | $1.3B | $1.3Bd | $1.3B | $1.4B | $1.4B | $1.5Bd | $1.4B |
| Gross margin | 58.6% | 59.3% | 60.8% | 61.2% | 61.8% | 62.2% | 58.8% | 61.5% |
| Operating income | $417.2M | $426.3M | $454.5Md | $446.5M | $491.7M | $499.8M | $448.7Md | $453.0M |
| Operating margin | 32.5% | 33.0% | 33.7% | 33.4% | 34.6% | 34.9% | 30.7% | 32.0% |
| Net income | $344.6M | $365.0M | $379.7Md | $348.5M | $392.6M | $398.7M | $383.4Md | $418.4M |
| Diluted EPS | $2.34 | $2.48 | — | $2.37 | $2.68 | $2.74 | — | $2.92 |
| Operating cash flow | $308.6Md | $578.7Md | $538.8Md | $457.3M | $339.7Md | $554.1Md | $454.6Md | $422.4M |
| Capital expenditure | $20.6Md | $20.8Md | $30.6Md | $43.0M | $28.5Md | $33.7Md | $51.1Md | $48.7M |
| Free cash flow | $288.0M | $557.9M | $508.2M | $414.4M | $311.2M | $520.5M | $403.5M | $373.7M |
| R&D expense | $81.4M | $83.9M | $86.4Md | $89.5M | $91.0M | $94.3M | $105.7Md | $102.9M |
From XBRL data in 10-Q and 10-K filings. d derived: a fourth quarter is the full year minus the first nine months, and cash flows are year-to-date figures differenced.
10-K and 10-Q filings
- 30 Oct 202610-Q for the period ended 30 Sep 2026SEC ↗
- 13 Aug 202610-K for the period ended 30 Jun 2026SEC ↗
- 1 May 202610-Q for the period ended 31 Mar 2026SEC ↗
- 30 Jan 202610-Q for the period ended 31 Dec 2025SEC ↗
- 31 Oct 202510-Q for the period ended 30 Sep 2025SEC ↗
- 8 Aug 202510-K for the period ended 30 Jun 2025SEC ↗
- 24 Apr 202510-Q for the period ended 31 Mar 2025SEC ↗
- 31 Jan 202510-Q for the period ended 31 Dec 2024SEC ↗